Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lixumistat
- Development stage
- Phase 1
- Lead developer
- ImmunoMet Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IM-156 (lixumistat) is a novel, orally bioavailable biguanide small molecule that acts as a potent inhibitor of mitochondrial protein complex I (PC1) within the oxidative phosphorylation (OXPHOS) pathway. By inhibiting OXPHOS, IM-156 induces metabolic stress and energy depletion in cancer cells that are highly dependent on mitochondrial respiration, particularly those that have developed resistance to standard treatments such as chemotherapy or PARP inhibitors. It also functions as an activator of AMP-activated protein kinase (AMPK). Developed by ImmunoMet Therapeutics, a spin-off from HanAll Biopharma, IM-156 is being evaluated in clinical trials for advanced solid tumors, including pancreatic cancer and glioblastoma, and is also being explored for non-oncology indications such as idiopathic pulmonary fibrosis (IPF).
- Other names
- IM-156 free baseIM156 free baseIM 156 free baselixumistatHL-156AHL156AHL 156AHL271HL-271HL 271
02
Targets
mTOR (Mammalian target of rapamycin kinase)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on lixumistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lixumistat.